Healthcare
Nuvation Bio Inc.(NUVB)
Live Price
Offline$5.56
+4.32% today
1Y Change
+173.40%
Window
Jun 25, 2025 โ Jun 15, 2026
- Market Cap
- $1.56B
- Revenue Growth
- +699.0%
- EPS Growth
- +71.6%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 25, 2025 โ Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Nuvation Bio Inc. (NUVB) is a Healthcare stock with a market cap of $1.56B and listed on NYSE. The stock last traded around $5.56 and up 173.4% across the available one-year price window (Jun 25, 2025 โ Jun 15, 2026). Baseline metrics include revenue growth of +699.0%, EPS growth of +71.6%, a dividend yield of 0.0%. What stands out right now is revenue +699.0%, EPS +71.6%, free cash flow -33.1% with operating margin -338.7% and ROIC -41.0%. Valuation already assumes a fairly strong business story at price/sales 24.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines NUVB price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+699.0% vs +7.6% peer median
Operating Margin
Below sector median
-338.7% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 6, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +699.0% and EPS at +71.6%, with operating margin around -338.7%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -11.5% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 6, 2026 | โ | -4.6% | -5.2% | +2.6% |
2026 Mar 2, 2026 | +0.0% | -25.3% | -19.0% | -30.7% |
2025 Nov 3, 2025 | +5.9% | -6.6% | -10.3% | +44.5% |
Benchmark Edge
NUVB vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
NUVB
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
NUVB Max Drawdown
-57.55%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for NUVB and SPY.
Company Overview
Nuvation Bio Inc.
New York Stock Exchange
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation; NUV-569, a differentiated oral small molecule selective inhibitor of the Wee1 kinase for DNA damage repair; NUV-1182, an adenosine receptor inhibitor; and drug-drug conjugate (DDC) platform that focuses on targeting an inhibitor of poly ADP ribose polymerase (PARP) to anti-cancer warheads of existing drugs, as well as PARP inhibitor to address ER+ breast and ovarian cancer. The company was formerly known as RePharmation Inc. and changed its name to Nuvation Bio Inc. in April 2019. Nuvation Bio Inc. was founded in 2018 and is headquartered in New York, New York.
- Leadership
- David T. Hung
- IPO Date
- Aug 26, 2020
- Employees
- 273
- Street Address
- 1500 Broadway
- Mailing
- New York City, NY, 10036
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 332 208 6102
- Last Updated
- May 2, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 24.7
- Price/Book
- 5.1
Growth
- Revenue
- +699.0%
- EPS
- +71.6%
- Free Cash Flow
- -33.1%
Profitability
- Gross Margin
- 86.6%
- Operating Margin
- -338.7%
- Net Margin
- -325.3%
- ROE
- -57.5%
- ROIC
- -41.0%
Balance Sheet
- Debt/Equity
- 0.03
- Current Ratio
- 6.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.